After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...

Some senior endocrinologists ThePrint spoke to underlined that the drug seems to be an innovation milestone, after the first global inhalable insulin Exubera, launched by New York-based ...

But in early April, the death blow was delivered: Pfizer, of New York, which in October had pulled its own inhaled insulin product, Exubera, from the market due to disappointing sales, said it is ...

“Exubera, the first inhaled form of insulin, has won the approval of the Higher Drugs Registration Committee at MoH,” disclosed Dr Issa bin Jakka Al Mansouri, Director of the Drug Control ...

The world's largest drug maker, Pfizer has announced that it intends to fast track its inhaled insulin Exubera in India. The world's largest drug maker, Pfizer has announced that it intends to ...

The market for new Reits has been closed for some time ...